180 related articles for article (PubMed ID: 10211151)
21. Potential cost savings to be made by slowing cognitive decline in mild Alzheimer's disease dementia using a model derived from the UK GERAS observational study.
Lenox-Smith A; Reed C; Lebrec J; Belger M; Jones RW
BMC Geriatr; 2018 Feb; 18(1):57. PubMed ID: 29471784
[TBL] [Abstract][Full Text] [Related]
22. Cost and care of patients with Alzheimer's disease: clinical predictors in German health care settings.
Reese JP; Hessmann P; Seeberg G; Henkel D; Hirzmann P; Rieke J; Baum E; Dannhoff F; Müller MJ; Jessen F; Geldsetzer MB; Dodel R
J Alzheimers Dis; 2011; 27(4):723-36. PubMed ID: 21876256
[TBL] [Abstract][Full Text] [Related]
23. Economic evaluation of hospital at home versus hospital care: cost minimisation analysis of data from randomised controlled trial.
Jones J; Wilson A; Parker H; Wynn A; Jagger C; Spiers N; Parker G
BMJ; 1999 Dec; 319(7224):1547-50. PubMed ID: 10591720
[TBL] [Abstract][Full Text] [Related]
24. Prospective one-year cost-of-illness study in a cohort of patients with dementia of Alzheimer's disease type in Spain: the ECO study.
Coduras A; Rabasa I; Frank A; Bermejo-Pareja F; López-Pousa S; López-Arrieta JM; Del Llano J; León T; Rejas J
J Alzheimers Dis; 2010; 19(2):601-15. PubMed ID: 20110605
[TBL] [Abstract][Full Text] [Related]
25. Alzheimer's disease in the UK: comparative evidence on cost of illness and volume of health services research funding.
Lowin A; Knapp M; McCrone P
Int J Geriatr Psychiatry; 2001 Dec; 16(12):1143-8. PubMed ID: 11748773
[TBL] [Abstract][Full Text] [Related]
26. Predictors of costs of care in Alzheimer's disease: a multinational sample of 1222 patients.
Gustavsson A; Brinck P; Bergvall N; Kolasa K; Wimo A; Winblad B; Jönsson L
Alzheimers Dement; 2011 May; 7(3):318-27. PubMed ID: 21575872
[TBL] [Abstract][Full Text] [Related]
27. Memantine: a pharmacoeconomic review of its use in moderate-to-severe Alzheimer's disease.
Plosker GL; Lyseng-Williamson KA
Pharmacoeconomics; 2005; 23(2):193-206. PubMed ID: 15748093
[TBL] [Abstract][Full Text] [Related]
28. Determinants of societal costs in Alzheimer's disease: GERAS study baseline results.
Dodel R; Belger M; Reed C; Wimo A; Jones RW; Happich M; Argimon JM; Bruno G; Vellas B; Haro JM
Alzheimers Dement; 2015 Aug; 11(8):933-45. PubMed ID: 25846298
[TBL] [Abstract][Full Text] [Related]
29. Costs and quality of life in community-dwelling patients with Alzheimer's disease in Spain: results from the GERAS II observational study.
Olazarán J; Agüera-Ortiz L; Argimón JM; Reed C; Ciudad A; Andrade P; Dilla T
Int Psychogeriatr; 2017 Dec; 29(12):2081-2093. PubMed ID: 28720158
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of full costs of care for patients with Alzheimer's disease in France: the predominant role of informal care.
Gervès C; Chauvin P; Bellanger MM
Health Policy; 2014 May; 116(1):114-22. PubMed ID: 24461717
[TBL] [Abstract][Full Text] [Related]
31. Social and economic costs and health-related quality of life in non-institutionalised patients with cystic fibrosis in the United Kingdom.
Angelis A; Kanavos P; López-Bastida J; Linertová R; Nicod E; Serrano-Aguilar P;
BMC Health Serv Res; 2015 Sep; 15():428. PubMed ID: 26416027
[TBL] [Abstract][Full Text] [Related]
32. Household members of persons with Alzheimer's disease: health conditions, healthcare resource use, and healthcare costs.
Suehs BT; Shah SN; Davis CD; Alvir J; Faison WE; Patel NC; van Amerongen D; Bobula J
J Am Geriatr Soc; 2014 Mar; 62(3):435-41. PubMed ID: 24576203
[TBL] [Abstract][Full Text] [Related]
33. Economic evaluation of donepezil in moderate to severe Alzheimer disease.
Feldman H; Gauthier S; Hecker J; Vellas B; Hux M; Xu Y; Schwam EM; Shah S; Mastey V;
Neurology; 2004 Aug; 63(4):644-50. PubMed ID: 15326236
[TBL] [Abstract][Full Text] [Related]
34. Monetary costs of agitation in older adults with Alzheimer's disease in the UK: prospective cohort study.
Morris S; Patel N; Baio G; Kelly L; Lewis-Holmes E; Omar RZ; Katona C; Cooper C; Livingston G
BMJ Open; 2015 Mar; 5(3):e007382. PubMed ID: 25770235
[TBL] [Abstract][Full Text] [Related]
35. Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK.
Ward A; Caro JJ; Getsios D; Ishak K; O'Brien J; Bullock R;
Int J Geriatr Psychiatry; 2003 Aug; 18(8):740-7. PubMed ID: 12891643
[TBL] [Abstract][Full Text] [Related]
36. Economic analysis of Alzheimer's disease in outpatients: impact of symptom severity.
Souêtre EJ; Qing W; Vigoureux I; Dartigues JF; Lozet H; Lacomblez L; Derouesné C
Int Psychogeriatr; 1995; 7(1):115-22. PubMed ID: 7579015
[TBL] [Abstract][Full Text] [Related]
37. Medical management, costs, and consequences of Alzheimer's disease in Germany: an analysis of health claims data.
Brüggenjürgen B; Andersohn F; Ezzat N; Lacey L; Willich S
J Med Econ; 2015 Jun; 18(6):466-73. PubMed ID: 25692902
[TBL] [Abstract][Full Text] [Related]
38. Patients with Alzheimer's disease living at home in France: costs and consequences of the disease.
Rigaud AS; Fagnani F; Bayle C; Latour F; Traykov L; Forette F
J Geriatr Psychiatry Neurol; 2003 Sep; 16(3):140-5. PubMed ID: 12967055
[TBL] [Abstract][Full Text] [Related]
39. Determinants of costs of care for patients with Alzheimer's disease.
Jönsson L; Eriksdotter Jönhagen M; Kilander L; Soininen H; Hallikainen M; Waldemar G; Nygaard H; Andreasen N; Winblad B; Wimo A
Int J Geriatr Psychiatry; 2006 May; 21(5):449-59. PubMed ID: 16676288
[TBL] [Abstract][Full Text] [Related]
40. A Real-World Evidence Analysis of Associations Among Costs, Quality of Life, and Disease-Severity Indicators of Alzheimer's Disease in Thailand.
Kongpakwattana K; Dejthevaporn C; Krairit O; Dilokthornsakul P; Mohan D; Chaiyakunapruk N
Value Health; 2019 Oct; 22(10):1137-1145. PubMed ID: 31563256
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
